The gamma delta T wave is cresting as industry leaders such as Adicet Bio, Leucid, Century, Imcheck, IN8bio, Sanofi and Takeda race to demonstrate the clinical benefit and efficacy of gamma delta T therapies, spanning cell-based to antibody and small molecule approaches. Spurred by early evidence of clinical efficacy, the industry returns in 2023 armed with more subset-specific and clinical mechanistic understanding, snowballing investment, and growing expert end-to-end teams. This is the prime time to gather with the gamma delta T therapies industry to contrast subsets, characterize mechanisms of action, and optimize product design to develop globally accessible, solid tumor therapies.

Ensure you don't miss this comprehensive, forward-facing summit, bringing together 150+ gamma delta T pioneers with 40+ industry-leading speakers including Adrian Hayday, Bruno Silva-Santos and Larry Lamb, collaborating and brainstorming approaches to tackle the most pressing hurdles in this burgeoning field.

Don't miss your chance to to enhance process development, overcome with expert learnings from the 4th Gamma Delta T Therapies Summit.

 Read on gamma-delta-t-therapies.com

Continue reading at gamma-delta-t-therapies.com

Health and Wellness

Facebook Share

Twitter Share

Linkedin Share

Email Share